Le Lézard
Classified in: Science and technology, Business
Subjects: BUSINESS CONTRACTS, Clinical Study

Reliq Health Technologies, Inc. Announces Go Live in Two Clinical Trials, New Contracts in TX and FL


HAMILTON, Ontario, May 19, 2022 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) ("Reliq" or the "Company"), a rapidly growing global healthcare technology company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that its iUGO Care platform will go live in two clinical trials this month involving over 1,000 patients. The Company also announced that it has signed four new contracts with clients in Texas and Florida that are expected to add over 2,000 patients to Reliq's iUGO Care platform in 2022.

"We are very pleased to be going live in our first clinical trials this month," said Dr. Lisa Crossley, CEO at Reliq Health Technologies, Inc. "Our Clinical Research Organization (CRO) client will be using Reliq's iUGO Care platform to monitor patients in two separate clinical trials focused on hypertension and oncology, respectively. Using iUGO Care for clinical trials allows CROs and trial sponsors to monitor trial-specific metrics such as medication adherence, side effects, safety issues and efficacy. These two trials are expected to add at least 1,000 patients to the iUGO Care platform this year and generate average revenue of $40 per patient per month at a gross margin of 75%. The Company has also signed four new contracts with two physician practices and two home health agencies that are expected to onboard over 2,000 new patients in Texas and Florida to Reliq's iUGO Care platform in 2022. Onboarding will begin next month and is expected to be completed by the end of the calendar year. The contracts are expected to generate an average revenue of over $60 per patient per month at 75% gross margin."

Reliq Health

Reliq Health Technologies is a rapidly growing global healthcare technology company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq's powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the Frankfurt Stock Exchange under the WKN: A2AJTB.

ON BEHALF OF THE BOARD
"Dr. Lisa Crossley"
CEO and Director

For further information please contact:

Company Contact
Investor Relations at [email protected]

US Investor Relations Contact
Investor Relations
Lytham Partners, LLC
Ben Shamsian
New York | Phoenix
646-829-9701
[email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the "Company") does not intend and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company's historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.

SOURCE: Reliq Health Technologies Inc.



These press releases may also interest you

at 08:05
Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today the enrollment of the first patient in a pilot study collecting patient-generated health data (PGHD) during proton radiotherapy for lung cancer in...

at 08:05
AVI Systems, the largest global audiovisual and unified collaboration systems integrator, today announced the launch of a new customer-focused offering called the AVI Experience. This initiative provides prospects and customers interested in...

at 08:05
Elite Robots, a leading supplier of collaborative robots, will exhibit its enriched range of cobots and all-in-one solutions at the upcoming Automate Show (May 6-9, Chicago), at booth 4255. After a successful 2023, in which Elite Robots experienced...

at 08:05
Edgio, the platform of choice for security, speed and simplicity at the edge, today announced the release of its Client-Side Protection solution. Designed to monitor scripts and APIs on the browser-side to prevent malicious code from exfiltrating...

at 08:05
Today, Stellar Cyber, the innovator of Open XDR, announced a new partnership with Acronis, a global leader in cybersecurity and data protection, to deliver an optimized threat detection and response solution enabling MSPs to protect on-premises,...

at 08:05
Roivant and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for...



News published on and distributed by: